MedTrace Logo

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

NCT02729376 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-09-04

No results posted yet for this study

Summary

This is an open label, single dose, 1 period study of \[14C\] galeterone.

Conditions

  • Healthy

Interventions

DRUG

galeterone

Sponsors & Collaborators

  • LTN PHARMACEUTICALS, INC.

    lead INDUSTRY

Principal Investigators

  • Karen J Ferrante, MD · Tokai Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02729376 on ClinicalTrials.gov